Levosimendan, a new calcium-sensitizing inotrope for heart failure

Pharmacotherapy

Volumn 24, Issue 10 II, 2004, Pages 1366-1384

  Ng, Tien M H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Heart failure; Inotropes; Levosimendan

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ADRENALIN; AMRINONE; CALCIUM SENSITIZER; CAPTOPRIL; CARVEDILOL; CATECHOLAMINE; DEXTROSIMENDAN; DIGOXIN; DOBUTAMINE; DOPAMINE; DRUG METABOLITE; FELODIPINE; FLOSEQUINAN; IBOPAMINE; INOTROPIC AGENT; ISOSORBIDE MONONITRATE; ITRACONAZOLE; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERANOMETOZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XAMOTEROL;

BLOOD LEVEL; CLINICAL TRIAL; DIASTOLE; DIZZINESS; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; HEADACHE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEMODYNAMICS; HUMAN; HYPOTENSION; INOTROPISM; NAUSEA; PROGNOSIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SINUS TACHYCARDIA; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; CALCIUM; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CLINICAL TRIALS; HUMANS; HYDRAZONES; MYOCARDIAL CONTRACTION; PYRIDAZINES; TREATMENT OUTCOME;

EID: 4644227135     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.14.1366.43145     Document Type: Review

References (76)

1. Greenberg B, Borghi C, Perrone S. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan? Eur J Heart Fail 2003;5:13-21.
2. Nielsen-Kudsk JE, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol 1995;26(suppl 1):S77-84.
3. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401.
4. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
5. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med 1991;325:1468-75.
6. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second prospective randomised study of ibopamine on mortality and efficacy (PRIME II) investigators. Lancet 1997;349:971-7.
7. Opie L. Mechanisms of cardiac contraction and relaxation. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine, 5th ed. Philadelphia: WB Saunders Company, 1997:360-93.
8. Mittmann C, Eschenhagen T, Scholz H. Cellular and molecular aspects of contractile dysfunction in heart failure. Cardiovasc Res 1998;39:267-75.
9. Balke CW, Shorofsky SR. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 1998;37:290-9.
10. Houser S, Piancentino V, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000;32:1595-607.
11. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995;27:2155-65.
12. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
13. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269:28584-90.
14. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
15. Boknik P, Neumann J, Kaspareit G, et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997;280:277-83.
16. Haikala H, Kaheinen P, Levijoki J, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997;34:536-46.
17. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7.
18. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
19. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994;81:974-87.
20. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995;26:179-88.
21. Pataricza J, Krassoi I, Hohn J, Kun A, Papp J. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003;17:115-21.
22. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002;94:1427-33.
23. + channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
24. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Diesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31:741-9.
25. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316-25.
26. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan Cardiovasc Drugs Ther 2003;17:111-13.
27. Pataricza J, Hohn J, Petri A, Balogh A, Papp J. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-17.
28. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001;37:367-74.
29. Rump AF, Acar D, Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 1994;112:757-62.
30. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994;74:244-8.
31. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997;85:23-9.
32. Todaka K, Wang J, Yi GH, et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 1996;279:120-7.
33. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995;26(suppl 1):S45-51.
34. Du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999;290:505-14.
35. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5-11.
36. du Toit E, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001;86:81-7.
37. Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 2000;400:103-12.
38. Takahashi R, Talukder MA, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000;36:118-25.
39. 2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 2002;366:440-8.
40. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42:43-51.
41. Lilleberg J, Antila S, Karlsson M, Nieminen MS, Pentkainen PJ. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 1994;56:554-63.
42. Sandell EP, Hayha M, Antila S, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995;26(suppl 1):S57-62.
43. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-71.
44. Sandell E, Aalto T, Antila S, et al. The effects of severe congestive heart failure on the pharmacokinetics of levosimendan [abstr]. EurJ Clin Pharmacol 1997;52(suppl):55.
45. Sandell E, Antila S, Koistinen H, Pentikainen P. The effects of renal failure on the pharmacokinetics of levosimendan [abstr]. Therapie 1995;1st congress of the European association for clinical pharmacology and therapeutics, Paris, France, September 27-30, 1995:495.
46. Turanlahti M, Antila S, Rantanen S, Lehtonen L. Pharmacokinetics and safety profile of levosimendan in pediatric patients evaluated for cardiac surgery [abstr]. Intensive Care Med 1999;25(suppl):S72.
47. Figgitt PG, Gillies PS, Goa KL. Levosimendan. Drugs 2001;61:613-27.
48. Lilleberg J, Sundberg S, Hayha M, Akkila J, Nieminen MS. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994;47:267-74.
49. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-6.
50. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997;61:596-607.
51. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-28.
52. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
53. Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26(suppl 1):S63-9.
54. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators. Circulation 2000;102:2222-7.
55. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
56. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
57. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
58. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81-6.
59. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-31.
60. Luotolahti M, Lammintausta O, Ukkonen H, et al. Levosimendan, a calcium sensitizer and potassium channel opener, is safe and improves left ventricular function in acute myocardial infarction. Circulation 1998;98(suppl):1105-6.
61. Sonnatag S, Opitz C, Wellnhofer E, et al. Effects of the calcium sensitizer levosimendan on stunned myocardium after percutaneous transluminal coronary angioplasty [abstr]. Eur Heart J 2000;21(suppl):40.
62. Packer M, Colucci WS, Fisher L, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study [abstr]. J Card Fail 2003;9(suppl):S61.
63. Follath F, Hinkka H, Jager D, et al. Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol 1999;83:I21-5.
64. Heartwire. CASINO results: Should docs gamble on levosimendan? American College of Cardiology News. New Orleans, LA: theheart.org; 2004.
65. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003;5:101-8.
66. Nicklas J, Monsur J, Bleske B. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999;83:I12-15.
67. Binkley P, Nunziata E, Hatten P, Leier C. The positive inotropic agent levosimendan mediates increased cardiac output with progression of sympathovagal imbalance in patients with heart failure [abstr]. Circulation 2000;102(suppl II):II-720.
68. Singh B, Lilleberg J, Sandell E, Ylonen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999;83:I16-20.
69. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000;35:664-9.
70. Antila S, Eha J, Heinpalu M, et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996;49:451-8.
71. Lehtonen L, Antila S, Eha J. No pharmacodynamic interactions between a new calcium sensitizing drug levosimendan and a calcium antagonist drug felodipine [abstr]. Eur J Clin Pharmacol 1997;52(suppl):136.
72. Sundberg S, Lehtonen L. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 2000;55:793-9.
73. Lehtonen L, Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 2002;58:449-52.
74. Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol 2000;56:705-10.
75. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ. The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998;36:446-9.
76. Antila S, Jarvinen A, Akkila J, Honkanen T, Karlsson M, Lehtonen L. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Arzneimittelforschung 1997;47:816-20.